Status:
TERMINATED
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Lead Sponsor:
Johns Hopkins University
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
18-99 years
Brief Summary
This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.
Detailed Description
People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer ...
Eligibility Criteria
Inclusion
- All patients who have been enrolled in the following three trials will be included in the study:
- A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
Exclusion
- None
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 3 2021
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01875770
Start Date
January 1 2013
End Date
March 3 2021
Last Update
October 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wilmer Eye Institute
Baltimore, Maryland, United States, 21287